切换至 "中华医学电子期刊资源库"

中华普外科手术学杂志(电子版) ›› 2019, Vol. 13 ›› Issue (03) : 294 -297. doi: 10.3877/cma.j.issn.1674-3946.2019.03.025

所属专题: 文献

论著

探讨单侧多发性乳头状甲状腺微小癌采用甲状腺全切除术的优势
王玲1, 皮勇1, 王勇1,()   
  1. 1. 441021 湖北襄阳,湖北文理学院附属医院 襄阳市中心医院普外科
  • 收稿日期:2018-05-15 出版日期:2019-06-26
  • 通信作者: 王勇

Clinical advantages of total thyroidectomy in treating unilateral multiple papillary thyroid microcarcinoma

Ling Wang1, Yong Pi1, Yong Wang1,()   

  1. 1. General surgery, Xiangyang Central Hospital, Affiliated Hospital Of Hubei University of Arts and Science, Hubei Xiangyang 441021, China
  • Received:2018-05-15 Published:2019-06-26
  • Corresponding author: Yong Wang
  • About author:
    Corresponding author: Wang Yong, Email:
引用本文:

王玲, 皮勇, 王勇. 探讨单侧多发性乳头状甲状腺微小癌采用甲状腺全切除术的优势[J]. 中华普外科手术学杂志(电子版), 2019, 13(03): 294-297.

Ling Wang, Yong Pi, Yong Wang. Clinical advantages of total thyroidectomy in treating unilateral multiple papillary thyroid microcarcinoma[J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2019, 13(03): 294-297.

目的

本研究旨在探讨单侧多发性乳头状甲状腺微小癌(UMPTMC)应用甲状腺全切术治疗的优势。

方法

回顾性分析2014年9月至2016年9月首次手术治疗的UMPTMC患者90例,其中53例行单侧叶甲状腺切除术(HT),另外37例行全甲状腺切除术(TT)。采用Pearson卡方检验或Student’s t检验以及Kaplan-Meier方法绘制生存曲线并通过对数秩检验进行统计分析,随后单因素分析采用Cox比例风险法进行无病生存分析,P<0.05被认为有统计学意义。

结果

HT组的所有肿瘤的总直径> 10 mm比TT组中更为常见(39.6%比18.9%; P=0.046);TT组患者中央淋巴结转移的阳性率高于HT组(81.1%比60.4%; P=0.046);HT组中肿瘤复发的发生率高于TT病例(26.4%比2.7%; P=0.007); HT组6个月和11个月的无病生存率分别为90.6%(48/53)和73.6%(39/53),TT组分别为100%(37/37)和91.9%(34/37),HT患者的无病生存期显著短于TT患者(log-rank检验P=0.0059)。Cox’s比例风险法的单因素分析显示,男性、所有肿瘤的总直径> 10 mm和中央淋巴结转移是HT患者复发的危险因素。

结论

单侧多发性UMPTMC患者采用甲状腺全切除术可有效降低肿瘤复发率,有利于延长无病生存期,因此随着复发风险的增加,UMPTMC的初次手术更宜选用TT,特别是男性和总肿瘤直径大于10 mm的患者。

Objective

The purpose of this study was to investigate the advantages of total thyroidectomy in the treatment of unilateral multiple papillary thyroid microcarcinoma (UMPTMC).

Methods

Retrospective analysis of 90 patients with UMPTMC who underwent first operation from September 2014 to September 2016. Of these, 53 underwent unilateral lobar thyroidectomy (HT). The other 37 cases underwent total thyroidectomy (TT). Pearson chi-square test, Student’s t test and Kaplan-Meier method were used to plot the survival curve, and logarithmic rank test was used to score the survival curve. Subsequently, Cox proportional hazard analysis was used to analyze disease-free survival (P<0.05).

Results

The total diameter of all tumors in the HT group was >10 mm more common than in the TT group (39.6% vs.18.9%; P=0.046); the positive rate of central lymph node metastasis was higher in the TT group than in the HT group (81.1% vs. 60.4%) ; P=0.046); the incidence of tumor recurrence in the HT group was higher than in the TT case (26.4% vs. 2.7%; P=0.007). Disease-free survival rates were 90.6% (48/53) and 73.6% (39/53) in the HT group at 6 months and 11 months, and 100% (37/37) and 91.9% (34/37) in the TT group, respectively. Disease-free survival was significantly shorter in the HT group than in the TT group (log-rank test P=0.0059). Univariate analysis of Cox’s proportional hazard analysis showed that men, all tumors with a total diameter > 10 mm and central lymph node metastasis were risk factors for recurrence in HT patients.

Conclusion

Total thyroidectomy for unilateral multiple UMPTMC patients can effectively reduce the recurrence rate of tumor and prolongs the disease-free survival period. Therefore, with the increase of recurrence risk, TT is more appropriate for the initial operation of UMPTMC, especially for male patients and patients with total tumor diameter greater than 10 mm.

表1 90例UMPTMC患者不同术式两组患者的临床病理学分析[例(%)]
图1 90例UMPTMC患者不同术式两组患者的无病生存分析
图2 15例UMPTMC术后复发患者无病生存率两组比较
表2 15例UMPTMC患者复发病例的详细情况
表3 53例UMPTMC HT组Cox比例风险法对无病生存率进行单因素分析
表4 53例UMPTMC患者HT组Cox比例风险法对无病生存率进行多因素分析
[1]
田文,赵文新.腔镜分化型甲状腺癌根治术的难点和争议[J/CD].中华普外科手术学杂志(电子版),2018,12(6):451-454..
[2]
Torresan F, Cavedon E, Mian C, et al.Long-Term Outcome After Surgery for Medullary Thyroid Carcinoma: A Single-Center Experience[J]. World J Surg, 2018, 42(2): 367-375.
[3]
Davies L, Welch HG. Current thyroid cancer trends in the United States[J]. JAMA Otolaryngol Head Neck Surg, 2014, 140(4): 317-322.
[4]
孙辉,李世杰,付言涛.分化型甲状腺癌功能性或传统性颈淋巴结清扫的利弊[J/CD].中华普外科手术学杂志(电子版),2018,12(6):455-457.
[5]
Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer[J]. Thyroid, 2016, 26(1): 1-133.
[6]
陈曦,陈海珍.甲状腺乳头状癌行预防性中央区淋巴结清扫的纷争[J/CD].中华普外科手术学杂志(电子版),2018,12(6):458-461.
[7]
Muller S, Senne M, Kirschniak A, et al. Impact of surgical resection extension on outcome for primary well-differentiated thyroid cancer-a retrospective analysis[J]. World J Surg Oncol, 2017, 15(1): 190-190.
[8]
Sharifi A, Shojaeifard A, Soroush A, et al. Predictors of Regional Lymph Node Recurrence after Initial Thyroidectomy in Patients with Thyroid Cancer[J]. J Thyroid Res, 2016, 4127278.
[9]
Dideban S, Abdollahi A, Meysamie A, et al. Thyroid papillary microcarcinoma: etiology, clinical manifestations, diagnosis, follow-up, histopathology and prognosis[J]. Iran J Pathol, 2016, 11(1): 1-19.
[10]
Kiriakopoulos A, Petralias A, Linos D. Multifocal versus solitary papillary thyroid carcinoma[J]. World J Surg, 2016, 40(9): 2139-2143.
[11]
Geller G, Laskin J, Cheung WY, et al. A retrospective review of the multidisciplinary management of medullary thyroid cancer: eligibility for systemic therapy[J]. Thyroid Res, 2017, 10: 6-6.
[12]
Wu ZG, Yan XQ, Su RS, et al. How many contralateral carcinomas in patients with unilateral papillary thyroid microcarcinoma are preoperatively misdiagnosed as benign? [J]. World J Surg, 2017, 41(1): 129-135.
[13]
Kim KJ, Kim SM, Lee YS, et al. Prognostic significance of tumor multifocality in papillary thyroid carcinoma and its relationship with primary tumor size: a retrospective study of 2, 309 consecutive patients [J]. Ann Surg Oncol, 2015, 22(1): 125-131.
[14]
Pyo JS, Sohn JH, Kang G. Detection of tumor multifocality is important for prediction of tumor recurrence in papillary thyroid microcarcinoma: a retrospective study and meta-analysis[J]. J Pathol Transl Med, 2016, 50(4): 278-286.
[15]
Huang G, Tian X, Li Y, et al. Clinical characteristics and surgical resection of multifocal papillary thyroid carcinoma: 168 cases[J]. Int J Clin Exp Med, 2014, 7(12): 5802-5807.
[16]
Spinelli C, Strambi S, Rossi L, et al. Surgical Management of Medullary Thyroid Carcinoma in Pediatric Age[J]. Curr Pediatr Rev, 2016, 12(4): 280-285.
[17]
Mishra A, Kumar C, Chand G, et al. Long-Term Outcome of Follicular Thyroid Carcinoma in Patients Undergoing Surgical Intervention for Skeletal Metastases[J]. World J Surg, 2016, 40(3): 562-569.
[18]
Qu HJ, Qu XY, Hu Z, et al. The synergic effect of BRAFV600E mutation and multifocality on central lymph node metastasis in unilateral papillary thyroid carcinoma[J]. Endocr J, 2018, 65(1): 113-120.
[19]
Kimbrell HZ, Sholl AB, Ratnayaka S, et al. BRAF Testing in Multifocal Papillary Thyroid Carcinoma[J]. Biomed Res Int, 2015, 2015: 486391.
[20]
Iwama E, Fujimura T, Kusakari Y, et al. Multifocal BRAF(V600E)-Mutated Melanoma in situ on the Foot[J]. Case Rep Dermatol, 2015, 7(3): 322-327.
[21]
Lu Z, Sheng J, Zhang Y, et al. Clonality analysis of multifocal papillary thyroid carcinoma by using genetic profiles[J]. J Pathol, 2016, 239(1): 72-83.
[1] 李永浩, 高雪菲, 郭田田, 张进, 张彩针, 刘静. 肥胖合并甲状腺癌相关机制的研究进展[J]. 中华普通外科学文献(电子版), 2023, 17(04): 311-315.
[2] 杨体飞, 杨传虎, 陆振如. 改良无充气经腋窝入路全腔镜下甲状腺手术对喉返神经功能的影响研究[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 74-77.
[3] 陈航, 闵翔. 日间甲状腺切除术后出血的12例临床分析及应对措施[J]. 中华普外科手术学杂志(电子版), 2023, 17(06): 600-602.
[4] 罗佳, 赵晶晶, 曹小珍, 钟玲, 范林军, 曾令娟. 单侧腋窝双侧乳晕入路机器人甲状腺术后局部加压预防皮下隧道出血的对照研究[J]. 中华普外科手术学杂志(电子版), 2023, 17(06): 603-606.
[5] 黄崇植, 肖映胜, 杨熙鸿, 林炘. 甲状腺下动脉的上行分支在甲状腺术中定位喉返神经的应用研究[J]. 中华普外科手术学杂志(电子版), 2023, 17(06): 607-610.
[6] 袁育韬, 邢金琳, 谢克飞, 殷凯. CT征象及BRAFV600E基因突变与甲状腺乳头状癌中央区淋巴结转移的相关性[J]. 中华普外科手术学杂志(电子版), 2023, 17(06): 611-614.
[7] 崔占斌, 乔军利, 张丽丽, 韩明强. 尿碘水平与甲状腺乳头状癌患者术后复发危险度分层的相关性[J]. 中华普外科手术学杂志(电子版), 2023, 17(06): 615-618.
[8] 陈垚, 徐伯群, 高志慧. 改良式中间上入路根治术治疗甲状腺癌的有效性安全性研究[J]. 中华普外科手术学杂志(电子版), 2023, 17(06): 619-622.
[9] 黄汇, 朱信强. 131I治疗45岁以下分化型甲状腺癌的疗效及影响因素[J]. 中华普外科手术学杂志(电子版), 2023, 17(06): 627-630.
[10] 江振剑, 蒋明, 黄大莉. TK1、Ki67蛋白在分化型甲状腺癌组织中的表达及预后价值研究[J]. 中华普外科手术学杂志(电子版), 2023, 17(06): 623-626.
[11] 樊丽超, 郭瑾瑛, 陈鑫. 野生型RET与RET/PTC融合基因检测对甲状腺乳头状癌中央区淋巴结清扫的指导意义[J]. 中华普外科手术学杂志(电子版), 2023, 17(06): 631-635.
[12] 徐成, 王璐璐, 王少华. 洗脱液甲状腺球蛋白在甲状腺乳头状癌转移淋巴结中的应用[J]. 中华普外科手术学杂志(电子版), 2023, 17(06): 701-704.
[13] 汪毅, 许思哲, 任章霞. 胸乳入路腔镜单侧甲状腺叶切除术与开放手术对分化型甲状腺癌患者术后恢复的影响[J]. 中华普外科手术学杂志(电子版), 2023, 17(05): 542-545.
[14] 张蓉, 秦洪真, 杨晓冬, 刘爽, 刘明锋, 曹秀堂. 分化型甲状腺癌术后康复锻炼的临床应用研究[J]. 中华普外科手术学杂志(电子版), 2023, 17(04): 439-442.
[15] 阳敏, 张婷, 钟玲, 刘军兰, 杜俊泽, 崔翔, 张晔, 范林军. 传统腔镜与达芬奇机器人手术治疗低危甲状腺癌的对比研究[J]. 中华普外科手术学杂志(电子版), 2023, 17(02): 176-179.
阅读次数
全文


摘要